poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy Rating and Raises Price Target for Revolution Medicines

Fiscal.ai

HC Wainwright & Co. reaffirmed its 'Buy' rating on Revolution Medicines and increased its price target for the company's stock to $350 from $280.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

    The European Commission has approved RASONQUE (daraxonrasib) by Revolution Medicines for treating adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The approval, based on positive Phase 3 RASolute 302 trial results, represents a significant advancement for pancreatic cancer treatment in the EU, with the company working to enable patient access through national pricing and reimbursement processes.